Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XTX 202

Next Previous
Search
Drug Profile

XTX 202

Alternative Names: XTX-202

Latest Information Update: 30 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akriveia Therapeutics
  • Developer Xilio Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 25 Mar 2025 Xilio Development completes a phase I/II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Inoperable/unresectable) in USA (Parenteral) (NCT05052268)
  • 31 May 2024 Updated efficacy, pharmacokinetic and adverse event data from a phase I/II trial in Renal cell carcinoma and Melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Mar 2024 Updated efficacy data from a phase I/II trial in Renal cell carcinoma and Melanoma released by Xilio Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top